Click to watch the live stream and join the conversation. #PhRMA16

0 SHARES

0

0

0

12

0 SHARES

0

0

0

12

Florida

Research In Your Backyard

Number Of Clinical Trials : 2,571


In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.

"With such facilities as M.D. Anderson Cancer Center Orlando, the Cleveland Clinic Florida, the University of Miami and the University of Florida, it’s not at all surprising that biopharmaceutical research companies have taken advantage of the state’s strong biopharmaceutical and life sciences infrastructure to conduct nearly 8,000 clinical trials of new medicines in Florida since 1999, including 3,840 for the most debilitating chronic diseases—cancer, diabetes, heart disease, stroke, asthma and mental illnesses."

Austin Curry, Executive Director, Elder Care Advocacy of Florida



  • 119,256

    Number Of Clinical Trial Participants


  • $963
    million

    Amount Invested In
    Clinical Trials


  • $2,681.7
    million

    Total Economic Impact Of Clinical Trial Investments

It takes about 10 years to develop one new medicine. Clinical trials are the most time- and resource-intensive part of the research and development (R&D) process for a new medicine, and biopharmaceutical companies support and conduct the lion’s share of this work. Yet without clinical trials, new medicines could not be approved and made available to the patients who need them.

Beyond the profound value that biopharmaceutical industry R&D brings patients in the form of new treatments and potential cures for society’s most devastating and costly diseases are the significant economic impacts resulting from clinical trials conducted in communities across the country.*



Learn more about Research in Your Backyard, a series of reports that highlight the importance of clinical trials to patients' health, as well as the contributions to local economies.

* The data presented here focuses solely on investments at clinical trial sites, which are only a portion of the full economic impact of R&D supported by the biopharmaceutical industry. In addition to excluding pre-discovery and preclinical research and other activities related to trial design, management coordination, and analysis, as well as any other activities occurring beyond the operations at the site level, were beyond the scope of this research. The report also excludes the large nationwide economic impact associated with non-R&D activities, including manufacturing and distribution.

connect with PhRMA...

Make your voice heard. Join the important discussion on the value and economic impact of new medicines.


connect with PhRMA...

Make your voice heard. Join the important discussion on the value and economic impact of new medicines.


  • +68K

    Followers

  • +57K

    Followers

  • 366

    Followers

  • 3343

    Subscribers